Philips installs 3-tesla MRI
The first Intera very high field scanner has been installed at the Institute of Biomedical Engineering, University and ETH in Zùrich, Switzerland. The institute has served as a key luminary site for Philips Medical Systems, having developed the
The first Intera very high field scanner has been installed at the Institute of Biomedical Engineering, University and ETH in Zùrich, Switzerland. The institute has served as a key luminary site for Philips Medical Systems, having developed the earliest version of the company’s Sensitivity Encoding (SENSE) technology. The potential of this technique and others will be explored on the 3-tesla product. Key projects will be investigations of epilepsy and the metabolism of glutathione and its role in psychiatric diseases. The higher signal-to-noise potential and scanning speeds possible on the 3-tesla system will allow studies of cardiac function and enhanced coronary MRA. Spectroscopic analyses of phosphorous metabolites such as ATP and phosphorous creatine will be used to examine cardiac contractility. The 3-tesla installation comes less than a year after Philips revealed plans to develop the product, which is designed for routine clinical as well as research scanning. The new product, along with an Intera 1.5-tesla scanner, will serve as the nucleus of a major MR research and competence center scheduled to open at the institute in the third quarter of this year.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
